Literature DB >> 34260666

COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes.

Adrianne L Jenner1,2, Rosemary A Aogo3, Sofia Alfonso4, Vivienne Crowe5, Xiaoyan Deng1,2, Amanda P Smith3, Penelope A Morel6, Courtney L Davis7, Amber M Smith3, Morgan Craig1,2,4.   

Abstract

To understand the diversity of immune responses to SARS-CoV-2 and distinguish features that predispose individuals to severe COVID-19, we developed a mechanistic, within-host mathematical model and virtual patient cohort. Our results suggest that virtual patients with low production rates of infected cell derived IFN subsequently experienced highly inflammatory disease phenotypes, compared to those with early and robust IFN responses. In these in silico patients, the maximum concentration of IL-6 was also a major predictor of CD8+ T cell depletion. Our analyses predicted that individuals with severe COVID-19 also have accelerated monocyte-to-macrophage differentiation mediated by increased IL-6 and reduced type I IFN signalling. Together, these findings suggest biomarkers driving the development of severe COVID-19 and support early interventions aimed at reducing inflammation.

Entities:  

Year:  2021        PMID: 34260666     DOI: 10.1371/journal.ppat.1009753

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


  16 in total

1.  Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy.

Authors:  Adrianne L Jenner; Munisha Smalley; David Goldman; William F Goins; Charles S Cobbs; Ralph B Puchalski; E Antonio Chiocca; Sean Lawler; Paul Macklin; Aaron Goldman; Morgan Craig
Journal:  iScience       Date:  2022-05-13

2.  Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms.

Authors:  Budhaditya Chatterjee; Harshbir Singh Sandhu; Narendra M Dixit
Journal:  PLoS Pathog       Date:  2022-06-27       Impact factor: 7.464

Review 3.  Advancing therapies for viral infections using mechanistic computational models of the dynamic interplay between the virus and host immune response.

Authors:  Veronika I Zarnitsyna; Juliano Ferrari Gianlupi; Amit Hagar; T J Sego; James A Glazier
Journal:  Curr Opin Virol       Date:  2021-08-24       Impact factor: 7.090

4.  A multicompartment mathematical model based on host immunity for dissecting COVID-19 heterogeneity.

Authors:  Jianwei Li; Jianghua Wu; Jingpeng Zhang; Lu Tang; Heng Mei; Yu Hu; Fangting Li
Journal:  Heliyon       Date:  2022-05-18

5.  Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients.

Authors:  Shun Wang; Mengqian Hao; Zishu Pan; Jinzhi Lei; Xiufen Zou
Journal:  PLoS Comput Biol       Date:  2021-11-24       Impact factor: 4.475

Review 6.  Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.

Authors:  Dimitrios A Vrachatis; Konstantinos A Papathanasiou; Sotiria G Giotaki; Konstantinos Raisakis; Charalampos Kossyvakis; Andreas Kaoukis; Fotis Kolokathis; Gerasimos Deftereos; Konstantinos E Iliodromitis; Dimitrios Avramides; Harilaos Bogossian; Gerasimos Siasos; George Giannopoulos; Bernhard Reimers; Alexandra Lansky; Jean-Claude Tardif; Spyridon Deftereos
Journal:  J Clin Med       Date:  2021-10-31       Impact factor: 4.241

7.  Human Cardiac Organoids to Model COVID-19 Cytokine Storm Induced Cardiac Injuries.

Authors:  Dimitrios C Arhontoulis; Charles Kerr; Dylan Richards; Kelsey Tjen; Nathaniel Hyams; Jefferey A Jones; Kristine Deleon-Pennell; Donald Menick; Diana Lindner; Dirk Westermann; Ying Mei
Journal:  bioRxiv       Date:  2022-02-01

8.  Executable network of SARS-CoV-2-host interaction predicts drug combination treatments.

Authors:  Rowan Howell; Matthew A Clarke; Ann-Kathrin Reuschl; Tianyi Chen; Sean Abbott-Imboden; Mervyn Singer; David M Lowe; Clare L Bennett; Benjamin Chain; Clare Jolly; Jasmin Fisher
Journal:  NPJ Digit Med       Date:  2022-02-14

9.  Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.

Authors:  Yuan Bai; Mingwang Shen; Lei Zhang
Journal:  Viruses       Date:  2022-04-06       Impact factor: 5.818

10.  Longitudinally monitored immune biomarkers predict the timing of COVID-19 outcomes.

Authors:  Gorka Lasso; Saad Khan; Stephanie A Allen; Margarette Mariano; Catalina Florez; Erika P Orner; Jose A Quiroz; Gregory Quevedo; Aldo Massimi; Aditi Hegde; Ariel S Wirchnianski; Robert H Bortz; Ryan J Malonis; George I Georgiev; Karen Tong; Natalia G Herrera; Nicholas C Morano; Scott J Garforth; Avinash Malaviya; Ahmed Khokhar; Ethan Laudermilch; M Eugenia Dieterle; J Maximilian Fels; Denise Haslwanter; Rohit K Jangra; Jason Barnhill; Steven C Almo; Kartik Chandran; Jonathan R Lai; Libusha Kelly; Johanna P Daily; Olivia Vergnolle
Journal:  PLoS Comput Biol       Date:  2022-01-18       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.